Insider Purchases: Inside the Buy

Tag: Absci

Biotechnology laboratory where artificial intelligence designs therapeutic antibodies, featuring DNA helices, glowing neural-network interfaces, hair follicle imagery, and an upward stock chart symbolizing Absci's AI-powered drug discovery platform.

🧬 Absci (ABSI): A Director Bought After a 5× Rally. Here's Why the Story May Still Be in Its Early Innings.

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

Tags: ABS-201, ABS201, Absci, AbsciCorp, ABSI, antibody discovery, BiotechStocks, buy or sell ABSI, clinical-stage biotech, Eli Lilly, EliLilly, featured-insiders, FUNanc1al, FunStock, GenerativeAI, genomics, hair loss treatment, HairRegrowth, hub-insiders, insider buying, InsiderBuying, Mary Szela, MarySzela, NASDAQ, precision medicine, risks buying ABSI, SeanMcClain, ShortSqueeze, why buy ABSI
Digital illustration of a DNA strand fusing with glowing AI circuitry inside a futuristic lab, symbolizing Absci’s generative AI drug discovery technology.

Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!

AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.

Read entire article

Tags: Absci, ABSI, ABSI Stock, AI, AI in Biotech, AI Stocks, Almirall, AMD, Ark Invest, Biotech, Biotech Humor, Biotech Innovation, Biotech Investing, Biotech Investments, Biotech Partnerships, Biotech Stocks, Buy ABSI Stock, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, Chief Innovation Officer Buying Shares, Director Insider Buying, drug discovery, FMR, Funanc1al, Funanc1al Edge, insider purchases, institutional ownership, investing humor, Oracle, Redmile Group, speculative stocks